1Q EARNINGS: Actavis not done shopping for growth
This article was originally published in Scrip
Executive Summary
Actavis isn't in the market for another mega-merger while it waits to close the $25bn acquisition of Forest Laboratories – unless, of course, the right deal comes along – but the long-time generic drug marketer and growing brand name pharmaceutical player is still shopping for assets that could boost the company's growth for the long term.